TCRαβ/CD19去除单倍体相合HSCT治疗儿童非恶性疾病
一项前瞻性研究纳入70例缺乏全相合供者或需紧急移植的儿童非恶性疾病患者,接受TCRαβ/CD19去除的单倍体相合HSCT。中位随访3.5年,5年总生存率和无病生存率分别为91.4%和86.8%,原发植入51例,移植相关死亡率累积发生率8.5%,仅1例发生轻度慢性GVHD。结论认为该策略有效,供者可及性好且GVHD发生率低。
要点
- TCRαβ/CD19去除单倍体HSCT可用于儿童非恶性疾病,5年OS达91.4%。
- 移植相关死亡率累积发生率8.5%,无III-IV级急性GVHD发生。
- 总体植入失败率30.4%,多发生于再生障碍性贫血和地中海贫血患儿。
核心结论
- TCRαβ/CD19去除的单倍体相合HSCT是儿童非恶性疾病的有效治疗选择。
- 供者快速可及、GVHD发生率低和移植相关死亡率低使该策略具有吸引力。
研究设计与样本
- 前瞻性研究,2012年1月至2020年4月连续纳入70例儿童非恶性疾病患者。
- 患者缺乏全相合供者或需紧急移植,接受HLA部分相合亲属的TCRαβ/CD19去除单倍体HSCT。
- 中位移植年龄3.5岁(范围0.3-16.1),中位诊断至移植时间10.5个月(SCID患者2.7个月)。
主要发现
- 原发植入51例,19例原发植入失败和2例继发植入失败,总体植入失败发生率30.4%。
- 植入失败多见于有风险的基础疾病患儿(如再生障碍性贫血、地中海贫血)。
- 除5例外,发生植入失败的患者均成功接受二次移植。
- 6例死于感染并发症(其中4例在HSCT时存在活动性或近期感染),移植相关死亡率累积发生率8.5%。
- 1-2级急性GVHD累积发生率14.4%,无患者发生3-4级急性GVHD;仅1例有风险患者发生轻度慢性GVHD。
临床怎么用
- 对于缺乏全相合供者或需紧急移植的儿童非恶性疾病患者,可考虑TCRαβ/CD19去除单倍体相合HSCT。
- 需关注植入失败风险,尤其是再生障碍性贫血和地中海贫血患儿,并准备二次移植预案。
- 移植前应积极控制活动性感染,以降低移植相关死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several nonmalignant disorders (NMDs), either inherited or acquired, can be cured by allogeneic hematopoietic stem cell transplantation (HSCT). Between January 2012 and April 2020, 70 consecutive children affected by primary immunodeficiencies, inherited/acquired bone marrow failure syndromes, red blood cell disorders, or metabolic diseases, lacking a fully matched donor or requiring urgent transplantation underwent TCRαβ/CD19-depleted haploidentical HSCT from an HLA-partially matched relative as part of a prospective study. The median age at transplant was 3.5 years (range 0.3-16.1); the median time from diagnosis to transplant was 10.5 months (2.7 for SCID patients). Primary engraftment was obtained in 51 patients, while 19 and 2 patients experienced either primary or secondary graft failure (GF), the overall incidence of this complication being 30.4%. Most GFs were observed in children with disease at risk for this complication (eg, aplastic anemia, thalassemia). All but 5 patients experiencing GF were successfully retransplanted. Six patients died of infectious complications (4 had active/recent infections at the time of HSCT), the cumulative incidence of transplant-related mortality (TRM) being 8.5%. Cumulative incidence of grade 1-2 acute GVHD was 14.4% (no patient developed grade 3-4 acute GVHD). Only one patient at risk developed mild chronic GVHD. With a median follow-up of 3.5 years, the 5-year probability of overall and disease-free survival was 91.4% and 86.8%, respectively. In conclusion, TCRαβ/CD19-depleted haploidentical HSCT from an HLA-partially matched relative is confirmed to be an effective treatment of children with NMDs. Prompt donor availability, low incidence of GVHD, and TRM make this strategy an attractive option in NMDs patients. The study is registered at ClinicalTrial.gov as NCT01810120.
引用
- Merli P, Pagliara D, Galaverna F, et al. TCRαβ/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders. Blood Adv. 2022. PMID: 34592755. doi:10.1182/bloodadvances.2021005628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。